Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05289180 · ClinicalTrials.gov registry record
Brachial Right Ventricle - Endomyocardial Biopsy
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 97
- Enrollment target
NCT05289180: Completed study, sponsored by NYU Langone Health.
NCT05289180 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 97 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05289180 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 97 participants
- Enrollment target
Study Summary
This is an observational study that will recruit NYU Langone patients undergoing standard of care right ventricle endomyocardial biopsy. Patients who undergo planned RV-EMB via transbrachial access will be invited to take part in the study.
Primary Outcome
Assessed by patients self report of their experience when undergoing right endomyocardial biopsy via brachial access compared to transjugular and transfemoral right ventricle endomyocardial biopsy.
Interventions
- OTHER Questionnaires
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2022-10-24 |
| Est. Completion | 2023-12-08 |
What the finished NCT05289180 record still lists
NCT05289180 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 97 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Questionnaires is the first listed.
NCT05289180 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05289180 about?
NCT05289180 is a clinical study titled "Brachial Right Ventricle - Endomyocardial Biopsy". This is an observational study that will recruit NYU Langone patients undergoing standard of care right ventricle endomyocardial biopsy. Patients who undergo planned RV-EMB via transbrachial access will be invited to take part in the study.
What is the current status of trial NCT05289180?
This trial is currently completed. The enrollment target is 97 participants. The study started on 2022-10-24. Estimated completion is 2023-12-08.
What interventions are being tested in trial NCT05289180?
The interventions under investigation include: Questionnaires (OTHER).
Who is sponsoring clinical trial NCT05289180?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI